|
![]() |
|
|
Famotidine
drug data and news
Famotidine drug data, resources, and news articles (when available). Onconews.org provides news on cancer research. This section, which includes profiles on medicines that may or not be cancer-related is in beta form. If things run smoothly we will be releasing a new format late in the summer of 2006.
|
| Generic name | Famotidine | ||
| Brand Names/Synonyms | Amfamox; Antodine; Apo-Famotidine; Apogastine; Bestidine; Blocacid; Brolin; CHEMBANK1161; Cepal; Confobos; Cronol; Cuantin; Dibrit 40; Digervin; Dinul; Dipsin; Dispromil; Dispronil; Duovel; Durater; Evatin; FAMOTIDINE, 99%; Fadin; Fadine; Fadyn; Fagastine; Famo; Famocid; Famodar; Famodil; Famodin; Famodine; Famogard; Famonit; Famopsin; Famos; Famosan; Famotal; Famotep; Famotidina [Spanish]; Famotidine; Famotidine Preservative Free; Famotidine Preservative Free in Plastic Container; Famotidine [Usan:Ban:Inn:Jan]; Famotidinum [Latin]; Famotin; Famovane; Famowal; Famox; Famoxal; Famtac; Famulcer; Fanobel; Fanosin; Fanox; Farmotex; Ferotine; Fibonel; Fluxid; Fudone; Ganor; Gaster; Gastridan; Gastridin; Gastrion; Gastro; Gastro: Gastrodomina; Gastrodomina; Gastrofam; Gastropen; Gastrosidin; H2 Bloc; HSDB 3572; Hacip; Huberdina; Ifada; Ingastri; Invigan; Lecedil; Logos; MK 208; Mensoma; Midefam; Mosul; Motiax; Muclox; Mylanta; Mylanta Ar; Neocidine; Nevofam; Notidin; Novo-Famotidine; Nu-Famotidine; Nulceran; Nulcerin; Panalba; Pepcid; Pepcid Ac; Pepcid Preservative Free in Plastic Container; Pepcid Rpd; Pepcidin; Pepcidin Rapitab; Pepcidina; Pepcidine; Pepdif; Pepdine; Pepdul; Pepfamin; Peptan; Peptidin; Peptifam; Pepzan; Purifam; Quamatel; Quamtel; Renapepsa; Restadin; Rogasti; Rubacina; Sedanium-R; Sigafam; Supertidine; Tairal; Tamin; Tipodex; Topcid; Ulcatif; Ulceprax; Ulcetrax; Ulcofam; Ulfagel; Ulfam; Ulfamid; Ulfinol; Ulgarine; Vagostal; Weimok; Whitidin; Yamarin | ||
| Indication | For treatment of Acid-reflux disorders (GERD – gastroesophageal reflux disease); Peptic Ulcer Disease | ||
| Sponsored links | Description | Not Available | |
| Pharmacology | Famotidine, a histamine H2-receptor antagonist, is used to treat gastrointestinal disorders such as gastric or duodenal ulcer, gastroesophageal reflux disease, and pathological hypersecretory conditions. Famotidine inhibits many of the isoenzymes of the hepatic CYP450 enzyme system. Other actions of Famotidine include an increase in gastric bacterial flora such as nitrate-reducing organisms. | ||
| Mechanism Of Action | Famotidine binds to an H2-receptor located on the basolateral membrane of the parietal cell, blocking histamine effects. This competitive inhibition results in reduced basal and nocturnal gastric acid secretion and a reduction in gastric volume, acidity, and amount of gastric acid released in response to stimuli including food, caffeine, insulin, betazole, or pentagastrin. | ||
| Famotidine News (When available) |
Wockhardt wins USFDA nod for Ranitidine OTC version Feb 27, 2006 Wockhardt receives US FDA approval for Ranitidine OTC version Feb 27, 2006 Common practice of prescribing H2 blockers to treat acid reflux in ... Feb 24, 2006 H 2 Blockers in Preemies Raise Necrotizing Enterocolitis Risk Feb 9, 2006 H 2 Blockers in Preemies Raise Necrotizing Enterocolitis Risk 09 Feb 2006 Common Reflux Treatment Linked To Life Threatening Bowel Infection ... 09 Feb 2006 Russian drug subsidies seen favoring Richter, Egis Dec 4, 2005 Are common drugs safe during pregnancy? Nov 14, 2005 The sky is the limit after 2006 Russian drug list - Citigroup on ... Nov 25, 2005 Holiday Treats Present Temptations and Challenges for Children ... Nov 22, 2005 Holidays Present Challenges for Children With GERD Nov 23, 2005 Holiday Treats Present Temptations and Challenges for Children ... Nov 22, 2005 Ask The Doctor: Nicotine patches also have adverse effects (The ... Oct 11, 2005 Ulcers mostly caused by bacteria, not stress Oct 24, 2005 Wockhardt net up 17% Oct 19, 2005 Prescribing medicine in Ramzan Oct 20, 2005 Wockhardt Q3 net vaults 17% to Rs 65 crore Oct 19, 2005 Pregnancy poses extra risks from drugs Oct 23, 2005 Bacteria Linked To Heart Risk Oct 7, 2005 The Efficacy of Preanesthetic Proton Pump Inhibitor Treatment for ... Sep 30, 2005 Off-Label Drug Use Oct 14, 2005 Ask The Doctor: Nicotine patches also have adverse effects (The ... 11 Oct 2005 Perrigo Company Announces Tentative Approval for Famotidine ... Sep 12, 2005 How Common Drugs Compare on Safety in Pregnancy Oct 10, 2005 Bacteria Linked To Heart Risk Oct 7, 2005 The Efficacy of Preanesthetic Proton Pump Inhibitor Treatment for ... Sep 30, 2005 Movers & Shakers Sep 13, 2005 Stocks to Watch Ford, Best Buy, Kroger Sep 12, 2005 (PRN) - The Plastic Surgery Group: Facelift Techniques Today Offer ... Sep 12, 2005 Nurse leads mission to Haiti Sep 22, 2005 Highlights of rising and falling US stocks Sep 13, 2005 Dr. Reddy's to sell ulcer drug in US Aug 20, 2005 Vindas to invest Rs 5 cr in Indore Aug 17, 2005 DEAR PHARMACIST Jul 19, 2005 Refining Emergency Severity Index Triage Criteria Jun 1, 2005 | ||
| Dosage Forms | SOLUTION; TABLET | ||
| Drug_Category | Anti-ulcer Agents; Histamine Antagonists; ATC:A02BA03 | ||
| Absorption | Absorption is incomplete, 40-45% | ||
| Interactions |
-->Interactions for Famotidine: No drug interactions have been identified. Studies with famotidine in man, in animal models, and in vitro have shown no significant interference with the disposition of compounds metabolized by the hepatic microsomal enzymes, e.g., cytochrome P450 system. Compounds tested in man include warfarin, theophylline, phenytoin, diazepam, aminopyrine and antipyrine. Indocyanine green as an index of hepatic drug extraction has been tested and no significant effects have been found. | ||
| Toxicity | Overdoses lead to emesis, restlessness, pallor of mucous membranes or redness of mouth and ears, hypotension, tachycardia and collapse. LD50=244.4mg/kg (i.v. in mice) | ||
| Organisms Affected | Humans and other mammals | ||
| Chemical IUPAC Name | 4-[2-(amino-sulfamoylimino-methyl)ethylsulfanylmethyl]-2-guanidino-1,3-thiazole | ||
| Chemical Formula | C8H15N7O2S3 | ||
| Molecular Weight | 337.449 g/mol | ||
| Smiles String | C1=C(N=C(S1)N=C(N)N)CSCCC(=NS(=O)(=O)N)N | ||
| Melting Point | 163-164 °C | ||
| Water Solubility | 1.1 mg/mL | ||
| State | Solid, white to pale yellow crystalline compound | ||
| LogP/Hphobicity | -0.726 | ||
| Isoelectric Point | Not Available | ||
| Biotransformation | Hepatic | ||
| Half Life | 2.5-3.5 hours | ||
| Protein Binding [%] | 20% | ||
| RxList Link | RXlist | ||
| Sponsored links | |||
| Drug Reference |
http://www.drugs.com/cons/Famotidine.html http://www.rxlist.com/cgi/generic/famot.htm http://www.pharmgkb.org/views/index.jsp?objId= | ||
| Drug Type | Approved Drug | ||
| Accession No | APRD00296 | ||
| CAS Registry Number | 76824-35-6 | ||
| KEGG Compound ID | D00318 | ||
| PubChem ID | SID:191368 | ||
| PharmGKB ID | PA449586 | ||
| SwissProt ID | Not Available | ||
| GenBank ID | Not Available | ||
| Drug ID Number [DIN] | 2241372 |
|
Home | About | Cancers | Treatment | Medications Copyright onconews.org 2005. All Rights Reserved. |